- Home
- KROS vs DIAX Comparison
KROS vs DIAX Comparison
Compare KROS & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | DIAX |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.0M | 528.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | DIAX |
|---|---|---|
| Price | $21.28 | $14.99 |
| Analyst Decision | Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $22.20 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 96.6K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.93% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $246,718,000.00 | N/A |
| Revenue This Year | $6,876.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.66 | ★ N/A |
| Revenue Growth | ★ 37798.31 | N/A |
| 52 Week Low | $9.12 | $12.80 |
| 52 Week High | $22.55 | $15.12 |
Technical Indicators
Market Signals| Indicator | KROS | DIAX |
|---|---|---|
| Relative Strength Index (RSI) | 70.39 | 51.36 |
| Support Level | $20.78 | $15.09 |
| Resistance Level | $22.20 | $15.31 |
| Average True Range (ATR) | 0.94 | 0.14 |
| MACD | 0.25 | 0.01 |
| Stochastic Oscillator | 76.47 | 52.15 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.